Press releases

Two-year follow-up data from TAXUS VI clinical trial consistent with results for slow-release TAXUS formulation.

Results presented are among the most comprehensive intravascular ultrasound (IVUS) follow-up data of any drug-eluting stent randomized clinical trial.

Research may signal new hope for the estimated 18.8 million Americans suffering from depression and four million from AD.

Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.

The Paris Course on Revascularization (EuroPCR) runs from May 24 to 27; read the schedule highlights.

Results were presented in oral and poster sessions at the Digestive Disease Week (DDW) 2005 conference.

A live webcast and replay of the Tuesday, May 17 session will be available. Learn how to tune into the presentation.

A live webcast and replay of the May 3 conference session will be available. Learn how to tune in for the presentation.

BEACH study evaluates the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease.

April 19 edition of JACC is a special issue devoted to the TAXUS IV trial.

"This was another record quarter, thanks in large part to the ongoing success of TAXUS," said Jim Tobin, President and CEO.

Acquisition would bring devices and procedures for treating abdominal aortic aneurysms (AAA).

Company currently distributes CryoVascular's angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.

NexStent™ recently received CE Mark for commercialization in Europe and certain other international markets.

Facility has received the prestigious NorthFace ScoreBoard Award for excellence in customer service for the second consecutive year.

SYNTAX trial will compare the performance of drug-eluting stents with cardiac surgery in the most complex patient subsets.

Award recognizes Company's accomplishments in creating a project-based system.

(April 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2005 on Tuesday, April 19, at 11:00...

A live webcast and replay of the April 12 conference session will be available.

Launch of Company's three large vessel TAXUS stent systems completes its line of sizes available in Europe and international markets.

With the indication, patients receiving the stent systems may safely undergo Magnetic Resonance Imaging (MRI) examination immediately following implantation.

Precision™ Spinal Cord Stimulation (SCS) System is a powerful new technology that provides many chronic pain sufferers a treatment option that is comfortable, long lasting and effective.

Company no longer markets or sells the NIR stent; findings will not affect Boston Scientific's ability to sell its market-leading TAXUS stent systems.

Company's Quincy Distribution Center approved as a sterilization site for its Cutting Balloon™ microsurgical dilatation device product line.

Company recognized for its achievements in lean manufacturing at its Minnesota facility